Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enterococcus hirae is a bacterial species that has been investigated for various biological roles, including its presence in gut microbiota, its involvement in food fermentation, and its potential as a probiotic or autoprobiotic. As an autoprobiotic, it has been studied for its effects on serum and urine metabolomes in patients with metabolic syndrome, suggesting a role in correcting metabolic imbalances. Certain strains of E. hirae, such as BNT6, produce bacteriocins (e.g., Enterocin BNT6) with broad-spectrum antimicrobial activity. Additionally, exopolysaccharides (EPS) derived from E. hirae, like glucan EPS from strain OL616073, have demonstrated prebiotic potential by resisting gastrointestinal digestion, stimulating probiotic growth, and modulating gut microbiota. The bacterium is also used as a test organism in evaluating the efficacy of disinfectants and has been identified as a reservoir for antimicrobial resistance genes in various animal populations. Its ability to degrade azo dyes has also been noted.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Enterococcus hirae.